Cellectis to Report Third Quarter Financial Results on November 12, 2026

Cellectis (CLLS) will report third-quarter 2026 financial results on November 12, 2026, after the close of the U.S. market.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Cellectis (CLLS) will report third-quarter 2026 financial results on November 12, 2026, after the close of the U.S. market.

The results cover the quarter ended September 30, 2026. An investor conference call and webcast will follow on November 13, 2026, at 8:00 a.m. ET / 2:00 p.m. CET, covering the quarterly results and an update on business activities.

Key Terms

base editing, epigenetic editing

2 terms

base editing technical

"spanning gene editing, base editing, epigenetic editing and transcriptional regulation."

A laboratory method that changes single “letters” in DNA to correct or alter genes without cutting the entire strand, like fixing a typo in a sentence rather than tearing out the page. It matters to investors because it promises faster, more precise treatments with potentially lower development costs and different safety and regulatory profiles than traditional gene therapies, which can speed clinical progress or create new commercial opportunities — and risks.

epigenetic editing technical

"spanning gene editing, base editing, epigenetic editing and transcriptional regulation."

Epigenetic editing is a method that changes chemical tags on DNA or its packaging to turn specific genes on or off without altering the underlying genetic code. Think of it like adding or removing sticky notes on an instruction manual to change which instructions are read. For investors, it matters because this approach can enable precise, potentially reversible treatments for diseases with different safety and regulatory profiles than permanent gene edits, affecting clinical value and commercial potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/09/2026 - 04:30 PM EST

NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will report financial results for the third quarter 2026 ending September 30, 2026 on Thursday, November 12, 2026 after the close of the U.S. market.

The publication will be followed by an investor conference call and webcast on Friday, November 13, 2026, at 8:00 a.m. ET / 2:00 p.m. CET. The call will include the Company’s third quarter 2026 results and an update on business activities. Details for the call are as follows:

Dial in information:
Toll Free US & Canada: +1-833-354-6854
US/International Toll: +1-785-838-9343
Conference ID: CLLSQ3
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1780016&tp_key=925efa50d7

About Cellectis

Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment. Leveraging decades of expertise in programmable DNA-binding proteins, the Company has built a differentiated genome engineering platform spanning gene editing, base editing, epigenetic editing and transcriptional regulation. By delivering the genomic intervention each disease requires, Cellectis is advancing a new generation of genetic medicines designed to move beyond disease management and toward lasting therapeutic impact.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit  www.cellectis.com  and follow Cellectis on  LinkedIn  and  X.  

For further information on Cellectis, please contact:         
     
Media contacts:              
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93      

Investor Relations contact:           
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment